INTERCEPT is not approved for sale in the United States and certain other countries.


INTERCEPT eNews delivers product news & information updates.

INTERCEPT Blood System for Platelets


The INTERCEPT Blood System for platelets has been shown to inactivate a variety of viruses. Of viruses tested to date, only HAV and PPV were resistant to inactivation. The results of these studies are summarized in Table 1.

Table 1. Inactivation Claims - Viruses

Viruses Tested Using
the INTERCEPT Blood System
Extent of Inactivation* (log10 reduction)
Platelets in plasma/Additive solution
Platelets in plasma
Enveloped Viruses
HIV-1 (cell-associated)***
HIV-1 (cell-free)
Clinical isolate of HIV-1
Clinical isolate of HIV-2
Latent proviral HIV-1
Inactivated to the limit of detection
HBV (strain MS-2)
HCV (strain Hutchison)
HTLV-I (Human T-cell Lymphotropic Virus)***
HTLV-II (Human T-cell Lymphotropic Virus)***
Cell-associated Cytomegalovirus (CMV)***
Bovine Viral Diarrhea Virus (BVDV, model virus for human HCV)
Duck Hepatitis B Virus (DHBV, model virus for human HBV)
4.4 to 4.5
PRV (Pseudorabies virus, model for CMV)
West Nile virus
SARS-CoV (Human Corona virus)
Chikungunya virus
Influenza A H5N1 virus (Avian Influenza)
Non-Enveloped Viruses 
Bluetongue Virus, type 11
1.7 to 2.4
Human Adenovirus-5
Parvo (Parvovirus B19)
* “>” refers to inactivation below the limit of detection of the assay. In some cases assays have a very small dynamic range due to limits on attainable virus titers.
** inherent low-level background in non-infected indicator cells precludes “>” of HTLV
*** intracellular
“-” means not tested

Previous PagePlatelet Technical Data Sheet Page 3 of 7Next Page

Untitled Document